Diabetes and endocrinology specialists at Riley Children’s Health deliver expert care for infants, children and adolescents with diabetes and other endocrine disorders. Our board certified physicians have completed additional subspecialty training in pediatric endocrinology and pediatric diabetology. Ten certified diabetes and education specialists provide a wide range of resources and support to patients and their families. DIABETES AND ENDOCRINOLOGY
RESEARCH HIGHLIGHTS
Research study site for breakthrough Type 1 diabetes therapies
Riley Children’s is a clinical trial site for therapies designed to modify the course of Type 1 diabetes, including a study examining the safety and efficacy of teplizumab in children younger than 8 years old with early-stage disease. In 2023, a patient at Riley Children’s became the first child in Indiana to receive teplizumab . As of early 2024, Riley Children’s has infused the youngest patient (22 months old) in the trial. Riley Children’s and the Herman B Wells Center for Pediatric Research are currently leading multiple diabetes and endocrine-related clinical trials, including the following for people with Type 1 diabetes: ■ TADPOL (Targeting Type 1 Diabetes via Polyamines) – Phase II study evaluating the efficacy and safety of difluoromethylornithine ■ JAKPOT T1D – National Institutes of Health (NIH)-funded Phase II trial evaluating janus kinase inhibitors abrocitinib and ritlecitinib ■ RELAY – NIH-funded trial testing sequential
DIVISION CHIEF Linda A. DiMeglio, MD, MPH Professor of Pediatrics, IU School of Medicine > Connect with Dr. DiMeglio on Doximity.
PROGRAM DISTINCTIONS
Specialized programs ■ Comprehensive Care Center for Congenital Adrenal Hyperplasia ■ Endocrine Diseases Newborn Screening Program ■ Type 1 Diabetes Program (including early-stage Type 1 diabetes) ■ Type 2 Diabetes Program ■ Youth Diabetes Prevention Program ■ Prader-Willi Syndrome Program ■ Metabolic Bone Disease Program ■ Muscular Dystrophy Program ■ Gender Health Program ■ Disorders of Sex Development Program ■ Turner Syndrome Program ■ Late Endocrine Effects of Cancer Therapy Program ■ Telehealth Endocrine and Diabetes Program ■ Young Adult Diabetes Transition Program
■ Ranked among the leading pediatric diabetes and endocrinology programs in the nation by U.S. News & World Report ■ One of the first pediatric programs in the Midwest (and first in Indiana) to administer teplizumab (the first FDA-approved preventive treatment for Type 1 diabetes) ■ Only comprehensive care center in the Midwest for congenital adrenal hyperplasia ■ Active in clinical and translational research studies for diabetes and endocrine disorders
17 board certified physicians
>
See full team member list
NOTABLE PUBLICATIONS
JAMA: March 2023 Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial The New England Journal of Medicine: July 2023 Obesity in Adolescents Communications Medicine (Lond.): October 2023 Disease-Modifying Therapies and Features Linked to Treatment Response in Type 1 Diabetes Prevention: A Systematic Review Hormone Research in Paediatrics: January 2023 Patient and Parent Perspectives on Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia Journal of Pediatric Endocrinology and Metabolism: January 2023 Long-Term Experience With the Use of a Single Histrelin Implant Beyond One Year in Patients With Central Precocious Puberty
43 research publications in 2023
therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone
Professional organization affiliations VICE CHAIR Type 1 Diabetes TrialNet Linda A. DiMeglio, MD, MPH SECRETARY Pediatric Endocrine Society Erica A. Eugster, MD TREASURER Pediatric Endocrine Society
The diabetes program at Riley Children’s is accredited by the Association of Diabetes Care and Education Specialists.
John S. Fuqua, MD EDITORIAL BOARD Diabetes Care Emily K. Sims, MD
Refer a patient online
Annual Report 2023 – 2024
317.944.3889
Made with FlippingBook Digital Proposal Creator